These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2596473)

  • 1. Variable efficacy of calcium carbonate tablets.
    Kobrin SM; Goldstein SJ; Shangraw RF; Raja RM
    Am J Kidney Dis; 1989 Dec; 14(6):461-5. PubMed ID: 2596473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technological testing of calcium carbonate tablets for use in the treatment of renal osteodystrophy.
    Dal Zotto M; Ragazzi E; Realdon N; Dalla Fini G
    Farmaco; 1993 Jul; 48(7):989-1005. PubMed ID: 8397681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium carbonate 1250 mg/1260 mg: an effective phosphate binder.
    Taylor JE; Henderson IS; Stewart WK; Mactier RA
    Scott Med J; 1990 Apr; 35(2):45-7. PubMed ID: 2374904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pH on in vitro disintegration of phosphate binders.
    Stamatakis MK; Alderman JM; Meyer-Stout PJ
    Am J Kidney Dis; 1998 Nov; 32(5):808-12. PubMed ID: 9820451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D.
    Mortensen L; Charles P
    Am J Clin Nutr; 1996 Mar; 63(3):354-7. PubMed ID: 8602592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution of calcium carbonate preparations.
    Brennan MJ; Duncan WE; Wartofsky L; Butler VM; Wray HL
    Calcif Tissue Int; 1991 Nov; 49(5):308-12. PubMed ID: 1782571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute biochemical effects of calcium: comparison of two dosage forms of calcium carbonate (powder and effervescent tablets) and milk in healthy women].
    Zikán V; Roubal P; Stĕpán J
    Cas Lek Cesk; 2002 Mar; 141(4):127-31. PubMed ID: 12046257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical study on the influence of a fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide on the bioavailability of famotidine.
    Zhai Q; Fu J; Huang X; Xu B; Yuan YZ; Jiang T; Rong ZX; Chen HZ
    Arzneimittelforschung; 2008; 58(11):581-4. PubMed ID: 19137909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis.
    Pflanz S; Henderson IS; McElduff N; Jones MC
    Nephrol Dial Transplant; 1994; 9(8):1121-4. PubMed ID: 7800211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure.
    Tsukamoto Y; Moriya R; Nagaba Y; Morishita T; Izumida I; Okubo M
    Am J Kidney Dis; 1995 Jun; 25(6):879-86. PubMed ID: 7771484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral administration of calcium carbonate, aluminum hydroxide gel and dihydrotachysterol on renal acidosis.
    Ueda H; Ikeda H; Sasaki Y; Shioji R
    Tohoku J Exp Med; 1978 Jan; 124(1):1-11. PubMed ID: 635890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate-binding capacities of calcium and aluminum formulations.
    Lau AH; Kuk JM; Franson KL
    Int J Artif Organs; 1998 Jan; 21(1):19-22. PubMed ID: 9554821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitriol and calcium carbonate therapy in early chronic renal failure.
    Bianchi ML; Colantonio G; Campanini F; Rossi R; Valenti G; Ortolani S; Buccianti G
    Nephrol Dial Transplant; 1994; 9(11):1595-9. PubMed ID: 7870349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcium suppletion for patients who use gastric acid inhibitors: calcium citrate or calcium carbonate?].
    de Jonge HJ; Gans RO; Huls G
    Ned Tijdschr Geneeskd; 2012; 156(34):A4343. PubMed ID: 22914054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets.
    Meyer C; Cameron K; Battistella M
    CANNT J; 2012; 22(4):33-5; quiz 36-7. PubMed ID: 23413537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.